TMEM16A/ANO1 suppression improves response to antibody-mediated targeted therapy of EGFR and HER2/ERBB2.
Kulkarni S, Bill A, Godse NR, Khan NI, Kass JI, Steehler K, Kemp C, Davis K, Bertrand CA, Vyas AR, Holt DE, Grandis JR, Gaither LA, Duvvuri U.
Kulkarni S, et al. Among authors: steehler k.
Genes Chromosomes Cancer. 2017 Jun;56(6):460-471. doi: 10.1002/gcc.22450. Epub 2017 Apr 3.
Genes Chromosomes Cancer. 2017.
PMID: 28177558
Free PMC article.